Homepage
Healthcare · Biotechnology · United States · Updated May 10, 8:14pm
$1.09
Price
$2.4M
Market Cap
9
Employees
0.59
Beta
Hyung Heon Kim
CEO
Business Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Business History
Price Overview
Last updated: May 11, 2026 1:58pm (just now)$1.02
-0.07 (-6.42%)
Day Range
$1.01 – $1.15
52-Week Range
$1.00 – $19.03
50-Day MA
$1.43
200-Day MA
$6.08
Volume
230,131.00
Share Structure
Outstanding
2,201,448.00
Float
981,536.00
Free Float
44.6%
Moderate free float
— 44.6% of shares trade freely, ~55.4% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (1.0M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.15
Stock Price: $1.09
EPS (Diluted): -7.35
EPS (Diluted): -7.35
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.79
Stock Price: $1.09
Total Equity: $5.33M
Shares: 1,766,026
Total Equity: $5.33M
Shares: 1,766,026
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.58
Market Cap: $2.40M
Total Debt: $68,000
Cash: $10.28M
EBITDA: -$13.69M
Total Debt: $68,000
Cash: $10.28M
EBITDA: -$13.69M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$4.8M
Market Cap: $2.40M
Total Debt: $68,000
Cash: $10.28M
Total Debt: $68,000
Cash: $10.28M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$19,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$13.71M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$12.97M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-202.2%
Net Income: -$12.97M
Total Equity: $5.33M
Total Equity: $5.33M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-21.6%
Operating Income: -$13.71M
Tax Rate: 0.0%
Equity: $5.33M
Total Debt: $68,000
Cash: $10.28M
Tax Rate: 0.0%
Equity: $5.33M
Total Debt: $68,000
Cash: $10.28M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.93
Current Assets: $10.88M
Current Liabilities: $5.65M
Current Liabilities: $5.65M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $68,000
Long-Term Debt: $0.00
Total Debt: $68,000
Total Equity: $5.33M
Long-Term Debt: $0.00
Total Debt: $68,000
Total Equity: $5.33M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 1,766,026
Shares: 1,766,026
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.02
Total Equity: $5.33M
Shares: 1,766,026
Shares: 1,766,026
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-8.89
Operating CF: -$15.70M
CapEx: -$2,000
Shares: 1,766,026
CapEx: -$2,000
Shares: 1,766,026
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.09
Stock Price: $1.09
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$12.97M
Net Income: -$12.97M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MTVA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $72,000 | $28,000 | $7,000 | $24,000 | $19,000 |
| Gross Profit | $-72,000 | $-28,000 | $-7,000 | $-24,000 | $-19,000 |
| Operating Expenses | $15.3M | $19.6M | $15.9M | $28.8M | $13.7M |
| Operating Income | -$15.3M | -$19.6M | -$15.9M | -$28.8M | -$13.7M |
| Net Income | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| EBITDA | -$15.2M | -$11.8M | -$15.9M | -$28.8M | -$13.7M |
| EPS | $-1,742.40 | $-477.84 | $-27.06 | $-39.16 | $-7.35 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $16.4M | $33.4M | $22.4M | $16.0M | $10.3M |
| Total Current Assets | $16.6M | $33.5M | $22.5M | $16.1M | $10.9M |
| Total Assets | $16.8M | $33.5M | $22.8M | $16.3M | $69.1M |
| Current Liabilities | $2.2M | $11.8M | $6.0M | $8.3M | $5.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.2M | $11.8M | $6.1M | $8.3M | $63.8M |
| Total Equity | $14.6M | $21.8M | $16.7M | $7.9M | $5.3M |
| Retained Earnings | -$81.8M | -$95.8M | -$108.3M | -$135.9M | -$148.8M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.1M | -$11.7M | -$10.8M | -$24.7M | -$15.7M |
| Capital Expenditure | $-3,000 | $0 | $-50,000 | $-8,000 | $-2,000 |
| Free Cash Flow | -$15.1M | -$11.7M | -$10.8M | -$24.7M | -$15.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.3M | $17.0M | -$10.9M | -$6.4M | -$5.7M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$4.2M -$6.2M – -$2.1M
|
-$2.7M -$3.9M – -$1.6M
|
-$2.1M -$2.1M – -$2.1M
|
-$1.9M -$1.9M – -$1.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +61.1% | +75.0% | -242.9% | +20.8% |
| Operating Income Growth | -28.3% | +19.1% | -81.3% | +52.4% |
| Net Income Growth | +8.6% | +10.7% | -121.3% | +53.0% |
| EBITDA Growth | +22.8% | -35.1% | -81.3% | +52.5% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-01-23 | Woodworth Marshall H | A-Award | 28,000.00 | $0.00 | $0 |
| 2026-01-23 | Kim Hyung Heon | A-Award | 32,000.00 | $0.00 | $0 |
| 2025-08-12 | Woodworth Marshall H | G-Gift | 14,200.00 | $0.00 | $0 |
| 2025-06-30 | Glickman Mark A | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | GROVES JASON L | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | Tursi James Patrick | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | STRICKLAND D GORDON | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | KOVEN ANDREW I | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | Salsbury Michael | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-04 | Woodworth Marshall H | P-Purchase | 14,200.00 | $0.70 | $9,940 |
| 2025-05-08 | DONG-A ST CO., LTD | P-Purchase | 4,647,887.00 | $0.71 | $3.3M |
| 2025-03-01 | Woodworth Marshall H | F-InKind | 3,417.00 | $1.46 | $4,989 |
| 2025-03-01 | Kim Hyung Heon | F-InKind | 2,795.00 | $1.46 | $4,081 |
| 2024-11-30 | Kim Hyung Heon | F-InKind | 2,867.00 | $2.55 | $7,311 |
No community reviews yet for MTVA.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27